Eisele Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 23, 2025
Insider Transaction Report
Form 4
Eisele Jeffrey
Chief Development Officer
Transactions
- Sale
Common Stock
2025-01-22$30.43/sh−1,291$39,279→ 55,590 total
Footnotes (1)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 21, 2025.